Fibrosis Medication (NovFS)
Outline
Diabetes Medication 
Anti-obesity Medication 
Kidney Disease Medication 
Fibrosis Medication 
Retroperitoneal Fibrosis Medication Pipeline
NovFS
Program Target
Fibrosis
Patient Numbers
5 Million
Development Stage
Clinical Phase (I)/II
NovMetaPharma develops NovFS, a (pulmonary, hepatic, etc.) fibrosis medication of first-in-class new substance.
NovMetaPharma has identified excellent anti-inflammatory and anti-fibrotic efficacies in NovFS (fibrosis medication) cell and animal testing. This confirmed the possibility of developing NovFS as fibrosis medication, and based on this, NovMetaPharma is conducting joint R&D of NovFS.
Treatment effects of idiopathic pulmonary fibrosis
Decrease of major mechanism gene expression causing idiopathic pulmonary fibrosis
Decrease of mediator genes (ECM) causing idiopathic pulmonary fibrosis